EP3 Receptor E2 variant Ab
| Catalog# | Product Description | Host Species | Nature | Cross reactivity | Quantity | Volume | Price |
|---|---|---|---|---|---|---|---|
| EP3-321AP | Affinity purified EP3 IgG | Rabbit | Affinity purified IgG | r, m, h | 100.0 ug | 150-500ul |
$245.00
|
| FITC-EP3II | FITC-conjugated antibody | Rabbit | FITC-conjugated antibodies | r, m, h | 100.0 ug | 150-500ul |
$350.00
|
| P-EP3II | Antigenic blocking peptide | n/a | Synthetic peptide | n/a | 250.0 ug | 100ul |
$125.00
|
| PC-EP3II | WB positive control for EP3II | n/a | Protein in ready-to-use bufer | n/a | 0.0 ug | 150ul |
$185.00
|
Eicosanoids exert their cellular action through specific G-protein coupled receptors. Prostanoids are the products of cyclooxygenases action on C-20 unsaturated fatty acids that are released by action of phospholipase A2 form cell membranes in response to various stimuli. Prostagandin E2 is the major prostanoid produced as a consequence of inflammation. Various PGE2 mediate defects on smooth muscle, vascular smooth muscle, muscle tone, renal salt and water re-absorption and rennin release has been described. Rapid progress has been made in cloning of members of the family of eicosanoid receptors. Kidney is the major site of arachidonic acid release and its subsequent enzymatic conversion to bioactive prostanoids via cyclo-oxygenase metabolic pathway. PGE2 is the only prostanoid described for which there are four E-Prostanoid receptors (designated EP1, EP2, EP3 and EP4) which have been shown to mediate a variety of effects of prostaglandin E2 (PGE2) on kidney glomerular heamodynamics, tublar salt and water reabsorption and on renal vasculature (1). EP3 receptors cause smooth muscle contraction in chick ileum and inhibit acid secretion in rat gastric mucosa, are activated by both sulprostone and AY 23636, but are not antagonized by SC19220 (2). EP3 receptors are negatively coupled to adenylate cyclase and upon activation decrease the cellular levels of cAMP (3). The EP3 have multiple variants that are expressed in glomeruli, Tamm-Horsefall negative late distal convoluted tubules, connecting segments, cortical and medullary collecting ducts as well as in the media and endothelial cells of arteries and areterioles (2).
The EP3 receptor protein is approx. 55 kDa (405 amino acids) protein which has 7 transmembrane domains, characteristic of G-protein coupled receptors. The EP3 sequence analyses suggest the presence of 7 transmembrane domains, a characteristic feature of GPCR. The protein has putative N-glycosylation sites near the extra cellular N-terminal end of the proteins. The protein has a large 3rd intra cellular loop which might be the site for the interaction of G-proteins. The short carboxy terminal is intracellular and has putative post-translational sites.
The Anti-EP3II-selective antibody was generated against a conserved sequence near the C-terminal that is unique to EP3II protein only. The polyclonal antibody strongly labels a 55-60 kDa protein in PC-EP3II samples. Anti-EP3II-selective antibody is also available in affinity-purified form for Immunoprecipitation, immunohistochemistry and Western blotting analyses. FabGennix Inc. will also conjugate antibodies with fluorescent probes upon request at extra charge. FabGennix Inc. also provides antibodies against several other GPCRs including Dopamine D1 and D2 receptors, chemokine receptors, and orphan receptors. FabGennix Inc., employs cyclic peptide methodology for generating antibodies, which results in higher titer and specificity (2). FabGennix, Inc., will also provide Western blot positive controls for most of these antibodies in ready-to-use buffer for easy identification of respective proteins. Limited quantities of antigenic peptides are also available. Please enquire for their availability before ordering.
For research use only, not for diagnostic or therapeutic use.
Data Sheets
MSDS
General Information
Citations
Search FabGennix Product Citation Data Base
Search